Cosmos Health reports 12,050 active U.S. subscriptions as of October 28
Cosmos Health said its active U.S. subscriptions reached 12,050 as of October 28, 2026, up 92% over two weeks, while monthly subscription value rose 94%.
Cosmos Health Inc. (NASDAQ:COSM) reported 12,050 active subscriptions on its U.S. direct-to-consumer platform as of October 28, 2026. The company said the figure was 92% higher than the 6,287 subscriptions reported on October 14, 2026.
Cosmos Health said active U.S. subscriptions reached 8,940 five days after the October 14 update, representing a 42% increase. The total then rose to 12,050, which the company reported as a 35% increase over nine days.
The company launched its U.S. subscription model in mid-July 2026 and began scaling it in mid-September 2026 while increasing investment in its U.S. platform.
Monthly subscription value increased 94% over the same two-week period, from $919,945 to $1,787,585. Cosmos Health defines the measure as the amount that would be billed in one month for active subscriptions at standard renewal pricing.
The figure is an operating metric rather than revenue under U.S. GAAP, and it does not represent revenue earned to date. Actual renewal revenue will depend on renewals, cancellations, pauses and skipped deliveries.
Online checkout orders tracked by the company’s platform reached 20,677. Cosmos Health reported this as a 41% increase from 14,624 on October 19, 2026, and a 90% increase from 10,881 on October 14, 2026.
Greg Siokas, chief executive officer of Cosmos Health, said the subscription base had reached 12,050 and that its monthly value had nearly doubled over two weeks. He described the model as recurring and said it was also live in Australia, New Zealand and the broader Oceania region.
Cosmos Health said it expects the recurring portion of U.S. revenue to increase as successive monthly subscriber cohorts renew. The company also stated that active subscriptions renew on a recurring basis, although the resulting renewal revenue will be affected by subscriber behaviour, including cancellations, pauses and skipped deliveries.
Cosmos Health describes itself as a diversified, vertically integrated global healthcare group. Its activities include proprietary pharmaceutical and nutraceutical brands, manufacturing through Cana Laboratories S.A., pharmaceutical and parapharmaceutical distribution through subsidiaries in Greece and the UK, research and development, and telehealth through ZipDoctor, Inc.
The company said its subscription and order figures came from platforms serving its U.S. online stores. The figures are preliminary and unaudited and may differ from amounts reported in its financial statements.
Cosmos Health announced an update on its U.S. direct-to-consumer subscription business. The company said active U.S. subscriptions reached 12,050 as of October 28, 2026, while monthly subscription value rose to $1,787,585 over the same two-week period.
Cosmos Health reported 12,050 active U.S. subscriptions as of October 28, 2026. The company had reported 6,287 active U.S. subscriptions on October 14, 2026, and said the total rose 42% to 8,940 five days later before reaching 12,050.
Cosmos Health said active U.S. subscriptions increased 92% in two weeks, from 6,287 on October 14, 2026 to 12,050 on October 28, 2026. The company also reported a 35% increase over nine days from 8,940.
Cosmos Health reported monthly subscription value of $1,787,585 as of October 28, 2026, compared with $919,945 two weeks earlier. The company defines this metric as the amount that would be billed on active subscriptions in a month at standard renewal pricing; it is an operating metric, not U.S. GAAP revenue, and does not represent revenue earned to date.
Cosmos Health said online checkout orders tracked by its platform rose to 20,677. This was up 41% from 14,624 on October 19, 2026 and up 90% from 10,881 on October 14, 2026.
Cosmos Health launched its U.S. subscription model in mid-July 2026 and began scaling it in mid-September 2026. The company said it accelerated investment in its U.S. platform during that period.
Cosmos Health said active subscriptions renew on a recurring basis, meaning each new subscriber represents an ongoing customer relationship rather than a single sale. The company expects the recurring portion of U.S. revenue to grow as successive monthly subscriber cohorts renew, although actual renewal revenue will depend on renewals, cancellations, pauses and skipped deliveries.
Greg Siokas, CEO of Cosmos Health, said active U.S. subscriptions had reached 12,050 and the monthly value of the subscription base had nearly doubled to almost $1.8 million over two weeks. He said the company viewed the growth as recurring and said the same model was live in Australia, New Zealand and the broader Oceania region.
Cosmos Health describes itself as a diversified, vertically integrated global healthcare group. It owns pharmaceutical and nutraceutical brands, manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices through Cana Laboratories S.A., distributes pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK, conducts research and development, and operates in telehealth through ZipDoctor, Inc.
Cosmos Health's shares trade on NASDAQ under the ticker symbol COSM, written in the source as NASDAQ:COSM.
Cosmos Health said the subscription and order figures were reported by its platforms for its U.S. online stores and were preliminary and unaudited. The company warned that they may differ from amounts reported in its financial statements, and said actual renewal revenue will depend on renewals, cancellations, pauses and skipped deliveries.